Study of AZD0754 in Participants With Metastatic Prostate Cancer

The purpose of this study is to evaluate the safety, tolerability, and antitumour activity of AZD0754 CAR T-cell therapy in participants with metastatic prostate cancer.

Trial Details

NCT ID
NCT06267729
Phase
PHASE1 / PHASE2
Sponsor
AstraZeneca
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • AZD0754
  • AZD2287
Locations (sample)
  • Duarte, California, United States|34.13945,-117.97729
  • Tampa, Florida, United States|27.94752,-82.45843
  • Atlanta, Georgia, United States|33.749,-84.38798
  • Westwood, Kansas, United States|39.04056,-94.6169
  • Boston, Massachusetts, United States|42.35843,-71.05977

Key Eligibility Criteria

  • Participant must be 18 years or older at the time of signing the informed consent form.
  • Type of Participant and Disease Characteristics
  • Participants with:
  • A histologically confirmed diagnosis of metastatic adenocarcinoma of the prostate without known neuroendocrine differentiation or small cell features.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →